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ABSTRACT
Abstract: Management of type 2 diabetes mel-
litus (T2DM) is complex and challenging, par-
ticularly for clinicians working in primary care
who are faced with many competing clinical
priorities. The range of available T2DM treat-
ments has diversified significantly in recent
years, generating a busy and data-rich environ-
ment in which evidence is rapidly evolving.
Sodium-glucose cotransporter-2 inhibitor
(SGLT2i) agents are a relatively new class of oral
glucose-lowering therapy that have been avail-
able in the UK for approximately 5 years. These
agents reduce the reabsorption of glucose in the
kidney and increase its excretion via the urine.
Conflicting messages and opinions within the
clinical community have led to misconceptions
concerning the efficacy, safety and appropriate
position of SGLT2i therapies within the T2DM
treatment pathway. To help address some of
these concerns and provide advice regarding the
appropriate place of these medicines in clinical
practice, the Improving Diabetes Steering
Committee was formed. The Committee
worked together to develop this review article,
providing a summary of relevant data regarding
the use of SGLT2i medicines and focusing on
specific considerations for appropriate prescrib-
ing within the T2DM management pathway. In
addition, a benefit/risk tool has been provided
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(see Fig. 3) that summarises many of the aspects
discussed in this review. The tool aims to sup-
port clinicians in identifying the people most
likely to benefit from SGLT2i treatments, as well
as situations where caution may be required.
Funding: Napp Pharmaceuticals Limited.
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THE ROLE OF THE IMPROVING
DIABETES STEERING COMMITTEE
The Improving Diabetes Steering Committee
comprises a panel of expert advisers from across
primary and secondary care who meet with the
objective of improving diabetes care. The Com-
mittee aims to ensure that UK prescribers of dia-
betes medicines have access to balanced and
accurate information/evidence concerning oral
type 2 diabetes mellitus (T2DM)medicines, with a
specific focus on the sodium-glucose cotrans-
porter-2 inhibitor (SGLT2i) class of treatments.
The group is committed to providing
healthcare colleagues with clarity concerning
the evidence base supporting SGLT2i agents,
highlighting the relative benefits and risks of
these therapies. Educational materials and
publications provided by the panel aim to
increase confidence and understanding regard-
ing the appropriate place of these medicines
within the current T2DM treatment paradigm.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
THE SGLT2 INHIBITOR CLASS
OF MEDICINES
Mechanism of Action
SGLT2 cotransporters are present in the early
proximal convoluted tubule (PCT) of the kidney,
where they actively reabsorb glucose to optimally
maintain blood glucose levels [1]. SGLT2i
medicines work independently of insulin to
selectively inhibit reabsorption of glucose in the
kidney, increasing excretion via the urine [1].
Three SGLT2i therapies are currently avail-
able for clinical use in the UK for the treatment
of T2DM: canagliflozin (distributed in the UK by
Napp Pharmaceuticals Limited), dapagliflozin
(AstraZeneca UK Limited) and empagliflozin
(Boehringer Ingelheim Limited) [2–4]. These
therapies are all very similar in terms of their
mechanisms of action, although canagliflozin is
known to also have affinity for SGLT1 cotrans-
porters found in the intestine and kidneys [2].
Phase 3 studies suggest that this property may
contribute to the enhanced postprandial glu-
cose-lowering action of canagliflozin 300 mg
compared with canagliflozin 100 mg [2].
UK Treatment Guidelines
Based upon available efficacy and safety data, the
National Institute for Health and Care Excellence
(NICE) and the Scottish Intercollegiate Guideline
Network (SIGN) recommend that SGLT2i thera-
pies can be considered alongside other glucose-
lowering medicines as an option at the first
intensification of treatment for T2DM, following
failure to achieve control with metformin, or as a
first-line treatment in cases of metformin intol-
erance [5–7]. SGLT2i medicines may also be used
as add-on third-line therapies. For example, they
may be used in combination with other glucose-
lowering agents such as oral therapies or gluca-
gon-like peptide 1 receptor agonists (GLP-1 RAs)
or with insulin [2–6]. Canagliflozin and empagli-
flozin may be prescribed in combination with
pioglitazone, but dapagliflozin is not approved for
combination treatment with pioglitazone [2–4].
Figures 1 and2present anoverviewof theNICE
and SIGN treatment algorithms for blood glucose-
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lowering and T2DM management, respectively
[5, 6]. Recommendations concerning SGLT2i
treatments apply across the class of medicines,
rather than to individual therapies or molecules
[5, 6].
Efficacy Data
SGLT2i therapies have demonstrated robust
efficacy outcomes concerning glycaemia, blood
pressure, intrarenal hemodynamic properties,
weight loss and albuminuria [8–18].
Reduction in Glycated Haemoglobin (HbA1c)
Each of the SGLT2i treatments available within
the UK have proven efficacy as monotherapies
and combination therapies [2–4]. Canagliflozin
has demonstrated efficacy in nine randomised
controlled trials (RCTs), involving 10,285 peo-
ple with T2DM, with the 300 mg dosage of
canagliflozin proving to be particularly effica-
cious in terms of glycaemic control [2, 10, 16].
Dapagliflozin has shown effective treatment
outcomes in 14 RCTs, conducted with 7056
people with T2DM [3]. The efficacy of empa-
gliflozin has been established in 12 RCTs
involving 14,663 T2DM individuals, with the
25 mg dosage providing additional improve-
ments in blood glucose control compared with
the 10 mg dosage [4, 12].
In addition, a systematic review and net-
work meta-analysis of RCT data (from January
2005 to January 2015) concerning SGLT2i
efficacy, compared with placebo, demonstrated
significant reductions in HbA1c with each
treatment when prescribed as monotherapy
and dual therapy, with few differences between
the class members concerning outcomes [11].
Compared with placebo, reductions in HbA1c
were greater with canagliflozin 300 mg
monotherapy (-1.23%) than with other SGLT2i
treatments or canagliflozin 100 mg [11].
Regarding dual therapy, canagliflozin 300 mg
achieved the greatest reductions in HbA1c,
although statistical significance was only
observed in comparison to canagliflozin
100 mg [mean difference 0.15; confidence
interval (CI) 0.04–0.26] [11].
Weight Loss
SGLT2i agents are associated with weight loss,
much of which is due to a reduction in visceral
fat, rather than urinary glucose excretion [8–10].
As a result, these treatments should be helpful for
individuals aspiring to lower or control their body
weight, an important factor and common feature
of T2DM management [19].
Cardiovascular (CV) Efficacy
A growing wealth of evidence from large RCTs
and observational studies demonstrates that
SGLT2i treatments reduce the risk of serious CV
complications, progression of kidney disease,
and death in people at risk of major adverse
cardiac events [12–18]. As a large proportion of
people living with T2DM also have an increased
risk of CV morbidities and mortality, these data
are particularly relevant and may have impli-
cations for clinical practice [20].
A recent network meta-analysis including 236
trials with 176,310 participants (published before
October 2017) has examined RCTs involving
SGLT2is, GLP-1 RAs and dipeptidyl peptidase-4
inhibitors (DPP-4is) [21]. The analysis showed that
SGLT2i treatmentsareassociatedwithsignificantly
reduced risk of all-cause mortality, heart failure
(HF) and myocardial infarction (MI) versus con-
trols (placebo or no treatment) [21]. The study also
revealed that the SGLT2is and GLP-1 RAs were
associatedwithsignificantly lower ratesofall-cause
mortality and CV events in published RCTs com-
pared with DPP-4is [21].
In recognition of the evidence in this area,
the SIGN 2017 guideline also recommends
using SGLT2i therapies with proven CV benefit
(currently empagliflozin and canagliflozin) for
those individuals with T2DM and established
CV disease (CVD) [6, 12, 16].
Key Published CV RCTs
Two large CV outcome trials, the EMPA-REG trial
and the CANVAS Program, have provided robust
data concerning CV endpoints [12–18]. These
trials are considered by the Improving Diabetes
Steering Committee to have an evidence level of
‘A’ under the American Diabetes Association
(ADA) evidence-grading system (also used to
support the benefit/risk tool, see Fig. 3) [22].
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Fig. 1 NICE treatment algorithm for blood glucose-lower-
ing therapy in adults withT2DM[5].NICE (2015)NG28
Type 2 diabetes in adults: management [5]. Available from:
http://www.nice.org.uk/guidance/ng28. All rights reserved.
Subject to Notice of rights. Requests to reuse NICE content
outside of the United Kingdom should be sent to nice@ni-
ce.org.uk.NICE guidance is prepared for theNationalHealth
Service in England. All NICE guidance is subject to regular
review and may be updated or withdrawn. NICE accepts no
responsibility for the use of its content in this product/pub-
lication. (Abbreviations: DPP-4i dipeptidyl peptidase-4
inhibitor, GLP-1 glucagon-like peptide-1, SGLT2i sodium-
glucose cotransporter-2 inhibitors, SU sulfonylurea). Rec-
ommendations that coverDPP-4is, GLP-1mimetics and SUs
refer to these groups of drugs at a class level. aWhen pre-
scribing pioglitazone, exercise particular caution if the person
is at high risk of the AEs of the drug. Pioglitazone is associated
with an increased risk of heart failure, bladder cancer and bone
fracture. Known risk factors for these conditions, including
increased age, should be carefully evaluated before treatment:
see the manufacturers’ summaries of product characteristics
for details. MHRA guidance (2011) advises that ‘prescribers
should review the safety and efﬁcacy of pioglitazone in indi-
viduals after 3–6 months of treatment to ensure that only
those deriving beneﬁt continue to be treated’. bSee NICE
Technology Appraisal Guidance 288 and 418, 315 and 336
on dapagliﬂozin, canagliﬂozin and empagliﬂozin, respectively.
All three SGLT-2 inhibitors are recommended as options in
dual therapy regimens with metformin under certain condi-
tions, as options in triple therapy regimens and in
combination with insulin. All three are also options as
monotherapies in adults in whom metformin is contraindi-
cated or not tolerated. Serious and life-threatening cases of
DKA have been reported in people taking SGLT2is (cana-
gliﬂozin, dapagliﬂozin or empagliﬂozin) or shortly after
stopping the SGLT2i. MHRA guidance (2015) advises test-
ing for raised ketones in people with symptoms of DKA, even
if plasma glucose levels are near normal. cOnly continueGLP-
1 mimetic therapy if the person has a beneﬁcial metabolic
response [a reduction of HbA1c by at least 11 mmol/mol
(1.0%) and aweight loss of at least 3%of initial bodyweight in
6 months]. dIf metformin is contraindicated or not tolerated,
repaglinide is both clinically effective and cost effective in
adults with type 2 diabetes. However, discuss with any person
for whom repaglinide is being considered that there is no
licensed non-metformin-based combination containing
repaglinide that can be offered at ﬁrst intensiﬁcation. eDrugs
in dual therapy should be introduced in a stepwise manner,
checking for tolerability and effectiveness of each drug.
fMHRA guidance (2011) notes that cases of cardiac failure
have been reported when pioglitazone was used in combina-
tion with insulin, especially in individuals with risk factors for
the development of cardiac failure. People should be observed
for signs and symptoms of heart failure, weight gain, and
oedema. Pioglitazone should be discontinued if any deterio-
ration in cardiac status occurs. gThe recommendations in this
guideline also apply to any current and future biosimilar
product(s) of insulin glargine that have an appropriate Mar-
ketingAuthorisation that allows the use of the biosimilar(s) in
the same indication
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EMPA-REG OUTCOME Trial [12]
The EMPA-REG OUTCOME trial examined the
efficacy and safety of empagliflozin in reducing
CV mortality and morbidity in 7020 people with
T2DM considered to be at a high risk of experi-
encing CV events [12]. Empagliflozin (10 or
25 mg) was administered in addition to standard
care, and CV outcomes were compared against
placebo. Median follow-up was 3.1 years and the
primary composite outcome was a reduction in
3-point major adverse CV events (3P-MACE),
comprising of death from CV causes, nonfatal MI
or nonfatal stroke [12]. The key secondary out-
come was a composite of primary endpoints and
hospitalisation for unstable angina [12].
The EMPA-REG OUTCOME trial met its pri-
mary endpoint, demonstrating a 14% relative
risk reduction (RRR) in 3P-MACE [hazard ratio
(HR) 0.86; 95.02% CI 0.74–0.99; P = 0.04 for
superiority]. Empagliflozin treatment was asso-
ciated with significantly lower rates of CV death
compared with placebo, with a RRR of 38% (HR
0.62; 95% CI 0.49–0.77; P\0.001) [12]. How-
ever, the study demonstrated no significant
difference concerning MI or stroke rates with
empagliflozin treatment versus placebo [12]. In
addition, compared with placebo, empagliflozin
treatment resulted in a RRR of 35% for hospi-
talisations due to HF (HHF) (HR 0.65; 95% CI
0.50–0.85; P = 0.002) and a 32% RRR for all-
Fig. 2 SIGN treatment algorithm for T2DM manage-
ment [6]. Algorithm summarises evidence from the
guideline in the context of the clinical experience of the
Guideline Development Group. It does not apply in severe
renal or hepatic insufﬁciency. 1Consider dose reduction.
2Do not delay if ﬁrst line options not tolerated/inappro-
priate. 3See guideline pages 23 and 26–27. 4See BNF:
speciﬁc agents can be continued at reduced dose. 5See
BNF: no dose reduction required for linagliptin. 6Piogli-
tazone is contraindicated in people with (or with a history
of) heart failure or bladder cancer. 7Do not combine
dapagliﬂozin with pioglitazone. 8Caution with exenatide
when eGFR\50 ml/min/1.73 m2. 9Adjust according to
response. 10Driving, occupational hazards, risk of falls,
previous history. Prescribers should refer to the British
National Formulary (www.medicinescomplete.com), the
Scottish Medicines Consortium (www.scottishmedicines.
org.uk) and Medicines and Healthcare products Regula-
tory Agency (MHRA) warnings for updated guidance on
licensed indications, full contraindications and monitoring
requirements. *Continue medication at each stage if
EITHER individualised target achieved OR HbA1c falls
more than 0.5% (5.5 mmol/mol) in 3–6 months. Dis-
continue if evidence that it is ineffective. CKD 3A chronic
kidney disease stage 3A (estimated glomerular ﬁltration
rate 45–59 ml/min/1.73 m2); CV cardiovascular
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cause mortality (HR 0.68; 95% CI 0.57–0.82,
P\ 0.001) [12]. Kidney function was main-
tained in the active treatment groups and the
incidence of renal events, including acute renal
failure and kidney injury, was lower in partici-
pants treated with empagliflozin [15].
A number of subsequent subanalyses have
been published that further explored the EMPA-
REG data. These demonstrated improvements
concerning CV endpoints in individuals across
the HHF risk spectrum and those with periph-
eral artery disease (PAD), and examined renal
outcomes within this cohort [13–15].
The CANVAS Program [16]
The Canagliflozin Cardiovascular Assessment
Study (CANVAS) Program comprised an inte-
grated analysis of data from two trials: CANVAS
and CANVAS-renal (CANVAS-R) [16]. CANVAS
examined CV safety outcomes and CANVAS-R
incorporated progression of albuminuria [23]. In
total, 10,142 people with T2DM and at high CV
risk were treated with canagliflozin (100 or
300 mg) or placebo, alongside standard T2DM
care [16, 23]. Mean follow-up was 188.2 weeks
[16, 23]. As with the EMPA-REG trial, the com-
posite primary endpoint was 3P-MACE [16]. Sec-
ondary outcomes were death from any cause, CV
death, progression of albuminuria, and the com-
posite of death from CV causes and HHF [16].
The CANVAS trial met its primary endpoint,
demonstrating a 14% RRR in 3P-MACE versus
placebo (HR 0.86; 95% CI 0.75–0.97; P\0.001
for noninferiority; P = 0.02 for superiority) [16].
Compared with placebo, a RRR of 27% was
observed concerning progression to albuminuria
with canagliflozin (HR 0.73; 95% CI 0.67–0.79). A
reduction in the composite exploratory outcome
of a sustained 40% reduction in the estimated
glomerular filtration rate (eGFR), need for renal
replacement therapy, or death from renal causes,
was also demonstrated with canagliflozin therapy
(HR 0.60; 95% CI 0.47–0.77) [16].
Real-World CV OUTCOME Studies
The EASEL Study [17]
EASEL was a US observational study of 25,258
people with T2DM and established CVD within
the US Department of Defence Military Health
System [17]. The study compared outcomes in
people receiving SGLT2i therapies with those of
individuals prescribed non-SGLT2i treatments,
and the median follow-up was 1.6 years [17]. The
primary endpoint was a composite of all-cause
mortality and HHF. In addition, MACE (com-
prising all-cause mortality, nonfatal MI and non-
fatal stroke), a composite of MACE and HHF, and
individual endpoints were assessed [17]. Of the
12,629 individuals receiving SGLT2i therapy,
58.1% were treated with canagliflozin, 26.5%
were prescribed empagliflozin and 15.4% received
dapagliflozin [17].
SGLT2i therapy was associated with lower
rates of the primary composite endpoint, com-
pared with non-SGLT2i treatment, with an
incidence rate of 1.73 versus 3.01 events per 100
person-years (HR 0.57; 95% CI 0.50–0.65) [17].
The all-cause mortality rate was reduced in
those receiving SGLT2i therapies compared
with non-SGLT2i treatments: 1.29 versus 2.26
events per 100 person years (HR 0.57; 95% CI
0.49–0.66; P\0.0001). The HHF rate was lower
with SGLT2i therapy: 0.51 versus 0.90 events
per 100 person years (HR 0.57, 95% CI
0.45–0.73; P\0.0001) [17]. The incidence of
MACE was also reduced in those treated with
SGLT2i agents compared with non-SGLT2i
treatments: 2.31 versus 3.45 events per 100
person years (HR 0.67; 95% CI 0.60–0.75) [17].
CVD-REAL [18]
CVD-REAL was an international observational
study comparing rates of HHF and death in
people receiving SGLT2i treatments with those
of other glucose-lowering therapies [18]. Data
were collated from 309,056 individuals newly
initiated on T2DM therapies (154,528 in each
group), using medical claims, primary care/
hospital records, and national registries in the
US, Norway, Denmark, Sweden, Germany and
the UK [18]. Of the SGLT2i agents examined,
canagliflozin accounted for 53%, dapagliflozin
for 42% and empagliflozin for 5% [18].
SGLT2i treatments were associated with lower
rates of HHF (pooled HR 0.61; 95% CI 0.51–0.73;
P\0.001), all-cause mortality (pooled HR 0.49;
95% CI 0.41–0.57; P\0.001) and the composite
outcome of death or HHF (pooled HR 0.54; 95%
CI 0.48–0.60; P\0.001) [18]. In addition, a
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recent subanalysis of the global CVD-REAL data
demonstrated a reduction in risk of MI (HR 0.85;
95% CI 0.72–1.00; P = 0.05) and stroke (HR 0.83;
95% CI 0.71–0.97; P = 0.02) with SGLT2i treat-
ments compared with other glucose-lowering
therapies [24].
These results reaffirmed the outcomes of the
EMPA-REG trial and CANVAS Program in real-
world practice [12, 16, 18]. No significant
heterogeneity was found concerning outcomes
across country settings. Most people included in
the analysis did not have established CVD and
had a lower CV-risk profile than those included
in the EMPA-REG and CANVAS trials, indicating
that a broader range of low-risk people with
T2DM may also benefit from the protective
effects of SGLT2i treatments in terms of reduc-
tion in CV events and mortality [18].
Ongoing CV and Renal Studies in T2DM
DECLARE-TIMI 58 [25, 26]
In line with the current focus on CV outcomes,
the ongoing Dapagliflozin Effect on Cardiovas-
cuLAR Events (DECLARE-TIMI 58) trial has been
designed to examine dapagliflozin treatment in
a high-risk T2DM population [25]. This multi-
centre RCT will examine treatment outcomes in
17,160 people with T2DM and CVD or multiple
risk factors for CVD (e.g. dyslipidaemia, hyper-
tension). Dapagliflozin (10 mg) treatment will
be compared against placebo in participants
receiving standard T2DM care [25].
The time to first event for the co-primary
endpoint of 3P-MACE (CV death, nonfatal MI
or nonfatal ischaemic stroke) and composite of
time to CV death or HHF will be assessed.
Secondary composite outcomes will com-
prise time to first event of the renal endpoint:
confirmed sustained C 40% decrease in eGFR
(to eGFR \60 ml/min/1.73 m2 [2]) and/or end-
stage kidney disease (ESKD) and/or renal or CV
death. Time to all-cause mortality will also be
assessed [25, 26].
CREDENCE [27, 28]
Although EMPA-REG and the CANVAS Program
have examined some exploratory renal end-
points, the Canagliflozin and Renal Events in
Diabetes with Established Nephropathy Clinical
Evaluation (CREDENCE) trial is the first dedi-
cated prospective renal RCT concerning SGLT2i
treatment in T2DM [12–16, 27, 28]. This study is
important for the SGLT2i class of medicines, as
people with T2DM and kidney disease are at
increased risk of CV events [29].
CREDENCE is a multicentre RCT comparing
canagliflozin (100 mg) with placebo in people
with T2DM and diabetic nephropathy who are
receiving standard care, including the maxi-
mum tolerated daily dose of an angiotensin-
converting enzyme inhibitor (ACEi) or an
angiotensin receptor blocker (ARB) [27, 28].
CREDENCE will assess the efficacy and safety
of canagliflozin in preventing clinically important
kidney and CV outcomes. The primary composite
endpoint is time to ESKD, doubling of serum
creatinine, and renal or CV death [27, 28].
Secondary endpoints include a composite of
CV death and congestive heart failure (CHF)
hospitalisation; a renal composite endpoint of
ESKD and a doubling of serum creatinine; CV
death and all-cause mortality; a CV composite
of 3P-MACE, CHF hospitalisation and unsta-
ble angina hospitalisation. The study is expec-
ted to enrol approximately 4400 people with
T2DM [27, 28].
Safety and Tolerability
As is the case with all medicines, clinical experi-
ence and emerging clinical data have revealed
factors that may influence the safety profile of
SGLT2i therapies, as well as highlighting certain
populations who may be at increased risk of tol-
erability issues. The main areas in which clini-
cians may require further support/guidance
concerning risk management are discussed below,
alongside the relevant published evidence.
Genital Infections
Genital infections (e.g. thrush) are a common
adverse event (AE) associated with SGLT2is
[12, 16, 30–32]. However, practical hygiene
advice for people with T2DM and their partners
may help to prevent this issue. Topical treat-
ments or appropriate oral treatments are helpful
for managing mild to moderate infections
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[30, 31]. Urinary symptoms due to glucosuria
can be an issue for people prescribed SGLT2i
medicines [2–4]. However, urinary tract infec-
tions (UTIs) are relatively rare and can be
addressed with standard oral antibiotic treat-
ments [30–32].
These are manageable issues that usually
occur early during treatment exposure and are
typically self-limiting [30, 31]. It is important to
manage people’s expectations at the start of
treatment so that they are aware of these com-
mon side effects and are able to tolerate them
better or seek medical support early before they
become an issue.
Lower Limb Amputations (LLAs) and Bone
Fractures
LLAs
Guidance issued by the European Medicines
Agency (EMA) Pharmacovigilance Risk Assess-
ment Committee (PRAC) has highlighted the
need for caution regarding the use of SGLT2i
treatments in those at high risk of LLAs [33]. The
report was issued as a result of a safety signal
raised during the CANVAS Program. Although
LLA incidence was low overall, a significant dif-
ference was observed concerning the number of
events that occurred in the treatment arm com-
pared with the placebo arm (Table 1) [16].
The EMA PRAC report has suggested that,
based on available reported data, a class effect
across all SGLT2i treatments cannot be ruled
out [33]. Evidence is conflicting in this area
[16, 34]. Overall, the crude LLA incidence rate
in the treatment arm was similar in the EMPA-
REG and CANVAS trials: 0.65 per 100 person
years and 0.63 per 100 person years, respectively
(Table 1) [16, 34]. However, in the EMPA-REG
trial, the LLA incidence was the same in the
pooled analysis for both the treatment and
placebo arms [34]. Although a higher number of
LLA events were recorded in the EMPA-REG
placebo arm than in the CANVAS trial placebo
arm (Table 1), key differences regarding the
design of these trials (e.g. study populations,
exposure times, primary endpoint assessments)
make direct comparisons impossible [16, 34].
The incidence of LLAs does not seem to be
dose dependent and the absolute risk appears to
be higher in people who have had a previous
amputation [16, 33]. The CANVAS study was
conducted in a relatively high-risk group,
including individuals with PAD and a history of
amputations, which may have increased the
likelihood of LLAs occurring in this cohort [16].
Observational data from the Food and Drug
Administration (FDA) Adverse Event Reporting
System (FAERS) identified 66 SGLT2i-associated
amputations among 9,217,555 AE reports filed
from across the globe [35]. Of these, the
majority included canagliflozin as a concomi-
tant medication, and most were toe amputa-
tions [35]. However, data from the large-scale
US Truven MarketScan database, including
119,567 people with T2DM who were receiving
SGLT2i therapies, revealed that there was no
increase in below-knee leg extremity (BKLE)
amputations with canagliflozin compared with
those receiving non-SGLT2i treatments
(Table 2) [17]. In contrast with the high-risk
CANVAS Program and EMPA-REG study popu-
lations, just 13% of this study cohort had
established CVD at baseline. In addition, the
BKLE incidence rate was comparable for those
receiving empagliflozin and canagliflozin (inci-
dence rate: 1.39 with empagliflozin versus 1.26
with canagliflozin per 1000 person years) [17].
It should also be noted that the number of
LLA events was very low in RCTs and observa-
tional studies compared with the number of
people with T2DM treated [12, 16, 17]. Global
pharmacovigilance data support this viewpoint
[36]. A recent analysis of World Health Organi-
zation (WHO) individual case safety reports
(ICSRs), including spontaneously reported
adverse drug reactions (ADRs), identified just 79
reports of LLAs associated with SGLT2is from a
total of 369,543 reports concerning blood glu-
cose-lowering agents. This analysis showed that
canagliflozin and empagliflozin were associated
with an increased proportional reporting ratio
(PRR) for LLAs, and dapagliflozin demonstrated
an increased PRR for toe amputations only.
However, pharmacovigilance data such as these
may be subject to limitations, as they are
dependent on accurate ADR reporting.
Appropriate advice for healthcare profes-
sionals has been issued by the UK Medicines
and Healthcare products Regulatory Agency
(MHRA) [37]. As with all people with T2DM, to
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minimise the risk of LLAs, ongoing monitoring
and advice regarding preventative footcare
should be provided, and it may be advisable to
avoid SGLT2i use in the individuals at greatest
risk, such as those with active foot ulceration or
previous amputation [2–4, 37].
Bone Fractures
Data are inconsistent concerning the risk of bone
fractures associated with SGLT2i therapies. EMPA-
REG data and dapagliflozin studies have not
demonstrated any meaningful differences con-
cerning bone mineral density (BMD) or fracture
incidence compared with placebo [9, 12].
Although the CANVAS trial highlighted a slight
increase in fracture incidence (15.4 canagliflozin
versus 11.9 placebo participants per 1000 person
years; HR 1.26; 95% CI 1.04–1.52), these out-
comes were not replicated in the CANVAS-R
population [16]. Fractures tended to occur early in
treatment and may have been linked to volume
depletion and exacerbated by falls associated with
hypotension [38]. In addition, studies examining
BMD in elderly people treated with canagliflozin
show only reductions in hip bone density, which
was not a site of fracture identified within the
CANVAS population, and may be partly due to
weight loss, as bone strength was retained
[16, 39].
Diabetic Ketoacidosis (DKA)
In 2015, the US FDA issued a safety communi-
cation regarding the risk of DKA in people with
T2DM treated with SGLT2i therapies, and a
warning was added to the label for each medi-
cine within the class [40]. This was subsequently
supported by the EMA and the MHRA, although
the EMA also stated that the benefits of these
medicines continue to outweigh the risks in the
treatment of T2DM [2–4, 40–42].
Cases of DKA in people treated with SGLT2is
are fairly rare [41, 42]. Risk factors that should
be considered include individuals who are rel-
atively insulin deficient (e.g. people with late-
onset autoimmune diabetes who have been
misdiagnosed as having type 2 diabetes), sud-
den reductions in insulin dose, increased
requirement for insulin (due to illness, surgery
or alcohol abuse), and conditions that restrict
food intake (particularly carbohydrate con-
sumption) or can lead to severe dehydration
[40–42]. People with T2DM should be advised of
the increased DKA risk associated with heavy
alcohol consumption [40, 41].
Key symptoms of DKA include nausea,
vomiting, abdominal pain, generalised malaise
and shortness of breath [40–42]. In people
treated with SGLT2is, DKA may present atypi-
cally, with relatively normal glucose levels
(euglycaemic ketoacidosis) [40]. The MHRA
recommend checking for raised ketone levels
when DKA symptoms are present, even if blood
glucose levels are near normal [41]. Where DKA
is diagnosed, SGLT2i therapy should be dis-
continued immediately [2–4, 40–42].
Acute Illness
In cases of acute illness or planned surgical
procedures, SGLT2i medicines should be sus-
pended immediately until the person has
recovered [2–4]. SGLT2i therapy may resume
following full recovery [2–4].
People with T2DM should follow the rec-
ommended sick day rules, which also apply to
some other medicines that people with T2DM
may take regularly (e.g. metformin), seeking
medical advice if they are unsure of how to
manage their medicines during this time
[43, 44].
Table 1 LLA event rate in the EMPA-REG and CAN-
VAS trials [16, 34]
LLA event rate per
100 person years
Relative risk
(95% CI)
Active
treatment
arm
Placebo
arm
CANVAS
program
[16]
0.63 0.34 1.97 (1.41–2.75)
EMPA-REG
[34]
0.65 0.65 1.00 (0.70–1.44)
Due to study design differences, direct comparisons cannot
be made across studies
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T2DM Sick Day Rules [43, 44]
During periods of illness, people with T2DM
should:
• Contact their diabetes team if they are
unsure about what to do,
• Stay well hydrated (3 l fluid/day) and eat
little and often,
• Keep taking insulin and/or most other
diabetes medications, but stop taking
SGLT2i, metformin and GLP-1 RA medici-
nes if they are unable to eat or drink, and
contact their diabetes team for further
directions,
• If possible, keep a close record of blood
glucose levels, at least every 4 h, including
during the night,
• If the blood glucose level is C 15 mmol/l,
urine/blood checks should be conducted
to test ketone levels. Medical assistance
should be sought when urine ketone levels
are[2 ?/or blood ketone levels
are[3 mmol/l,
• Maintain a normal meal pattern (where
possible). If unable to eat or appetite is
reduced, meals may be replaced with
high-carbohydrate snacks or drinks (e.g.
fruit juice, glucose tablets),
• If vomiting, drowsy, unable to keep fluids
down or suffering with persistent diar-
rhoea, medical help should be sought
immediately.
Considerations When Initiating SGLT2i
Therapies at an Early or Late Stage
in the T2DM Treatment Pathway
SGLT2i agents may provide an effective option
for people with T2DM at many stages along the
treatment paradigm. Due to the increasing vol-
ume of evidence relating to the efficacy and
safety profile of SGLT2i therapies in people with
T2DM and CVD, these medicines are generally
considered to be a logical option for many
people as first-line, second-line or third-line
therapy [5–7, 11–18].
As previously discussed, overweight or obese
people with T2DM may particularly benefit
from these therapies [8, 9]. SGLT2is may be
prescribed in combination with insulin,
although caution should be used in those
requiring an insulin dose reduction due to
insulinopenia, as they may be predisposed to
ketosis [2–4, 40, 42]. SGLT2is may also be used
in combination with GLP-1 RAs [2–4]. However,
there is less evidence available for the use of this
therapy combination [2–4].
Table 2 Crude incidence rate of BKLE amputation from the Truven MarketScan database [17]
Treatment Number of
individuals
Participants with
amputation before treatment
exposure
Participants with BKLE
amputation after treatment
exposure
Incidence rate per
1000 person years
All SGLT2i
treatments
11,567 225 171 1.22
Canagliﬂozin 73,024 139 120 1.26
Dapagliﬂozin 39,117 76 37 0.96
Empagliﬂozin 24,433 55 25 1.39
Non-SGLT2i
glucose-lowering
agent
226,623 722 530 1.87
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Regarding renal function, SGLT2i therapy
may be prescribed for people with
eGFR C 60 ml/min/1.73 m2. In those currently
treated with canagliflozin and empagliflozin,
treatment may continue until eGFR reaches
45 ml/min/1.73 m2 [2, 3]. Dapagliflozin may
not be prescribed for individuals with
eGFR\ 60 ml/min/1.73 m2 [4]. It is important
to note that a recent eGFR measurement should
be used in clinical decision making, rather than
historical measurements.
Malignancy is an important consideration
for people living with chronic conditions
such as T2DM. Phase III dapagliflozin studies
reported a small number of bladder cancer
cases, but these data were considered incon-
clusive concerning a causal relationship
[45, 46]. To date, the large-scale CANVAS and
EMPA-REG CV outcome trials have reported
no increase in cancer rates with canagliflozin
or empagliflozin [12, 16]. A recent meta-
analysis of SGLT2is concluded that current
evidence does not indicate an increased
overall risk of cancer with SGLT2i therapies
[47]. The DECLARE trial is expected to pro-
vide further insights concerning long-term
SGLT2i use in this area in the coming months
[25, 26].
SGLT2i therapies should be used with cau-
tion in those with very high HbA1c levels
(86 mmol/mol or 10%), frail/elderly people,
those with cognitive impairment, people who
have rapidly progressed to requiring insulin
(within one year of diagnosis) and individuals
with a low body mass index (BMI) [2–4]. SGLT2i
therapies should not be prescribed for people
with a history of DKA, pancreatic disease, sus-
pected type 1 diabetes, genetic diabetes or
pregnant/breastfeeding women (or those plan-
ning pregnancy) [2–4].
SGLT2i treatments are not currently recom-
mended for use with loop diuretics [2–4].
However, this may change over time as the
evidence base in high-risk CV populations,
particularly those with HF, continues to evolve
[27].
Steering Committee Advice Regarding
the Prescribing of SGLT2i Treatments
for People Receiving Diuretic
Medicines1
• Check electrolyte and renal function for
all indviduals prescribed SGLT2is. This is
particularly important for people on
diuretic therapies.
• Conduct regular electrolyte and renal
function measurements, as appropriate
for individual circumstances, comorbidi-
ties and concomitant medications. A mod-
est reduction in eGFR may be expected
following the initiation of SGLT2i ther-
apy, as is the case for other medications
such as ACEis.
• Consider reducing or stopping diuretic
medicines for treatment of oedema or
hypertension, especially if blood pressure
is well controlled.
• In line with NHS Scotland 2018 Polyphar-
macy Guidance, review medicines regu-
larly and de-escalate therapy where
possible [48].
SUMMARY AND PRACTICAL
CONSIDERATIONS
The SGLT2i class of medicines provides an
efficacious and generally well-tolerated treat-
ment option for the management of T2DM
[2–18]. A wealth of RCT and real-world evi-
dence supports the use of these therapies in
achieving and maintaining control of blood
glucose [8–18]. People with T2DM can experi-
ence weight loss with SGLT2i agents, which
encourages them to adhere to treatment [8, 9].
In addition, studies have also revealed the
cardio- and renoprotective aspects of these
medicines [12–18].
1 Please note that this advice is based upon expert
opinion and clinical experience as research is currently
ongoing in this area [27, 28].
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Education regarding the risks of minor AEs
such as genital thrush should be provided when
initiating SGLT2i treatment, in order to manage
people’s expectations and help them tolerate
early issues so that they may gain optimum
benefit from these medicines.
There are conflicting data concerning the
risk of LLAs and bone fractures with these
medicines, which has led to the EMA issuing a
PRAC report recommending caution when pre-
scribing all SGLT2i therapies in high-risk indi-
viduals (e.g. PAD, previous amputations)
[9, 12, 16, 33, 36]. Much debate is ongoing
within the clinical community regarding whe-
ther this is a real effect of these medicines or a
result of trial design and study population.
However, the crude number of LLA events
recorded in major CV outcome trials was rela-
tively low when compared with the number of
people who demonstrated improved outcomes,
such as a reduced risk of HHF or all-cause death
[16, 34]. SGLT2is provide an effective option for
many people with T2DM, including those with
CVD and people with no history of peripheral
vascular issues or LLAs. Ongoing monitoring
and preventative footcare advice should be
provided for those receiving SGLT2i medicines
[2–4, 37].
DKA cases are relatively rare in people trea-
ted with SGLT2i medicines [2–4, 41]. DKA
monitoring should be implemented, in line
with MHRA guidelines [41]. Key symptoms
include nausea, vomiting, abdominal pain,
generalised malaise and shortness of breath
[41].
SGLT2is may be initiated for appropriate
people with T2DM at any stage along the
treatment pathway where evidence supports
their use and comorbidities do not compromise
safety [5, 6].
The Improving Diabetes Steering Committee
has developed a benefit/risk tool, provided in
Fig. 3, that offers a quick reference guide con-
cerning the specific areas covered in this review.
The tool aims to provide clarity regarding
common areas of confusion in clinical practice
associated with the risk of LLAs and bone frac-
tures, late and early use of SGLT2i treatments
within the T2DM pathway, and risk of DKA.
The types of people or clinical situations that
are likely to be seen in practice are highlighted
in a traffic light system, in terms of risk:
• Low risk (green) A robust evidence-base sup-
ports SGLT2i prescribing in these situations.
• Moderate risk (amber) Prescribe SGLT2i agents
with caution (some evidence supporting a
benefit in these circumstances).
• High risk (red) Do not prescribe SGLT2is in
these situations (due to a lack of evidence,
high risk of AEs, or licence restrictions).
An evidence level has been assigned to each
risk category, based on RCT and observational
data, as well as NICE/SIGN guidelines and the
licensed indication for each therapy within the
SGLT2i class of medicines. The level of evidence
has been scored according to the ADA Evidence-
Grading System (summarised in Table 3) [22].
The tool aims to support clinicians in
selecting appropriate people with T2DM for
Table 3 ADA evidence-grading system for ‘‘Standards of
Medical Care in Diabetes’’ [22]
Grade
level
Description
A Clear evidence from well-conducted,
generalisable RCTs that are adequately
powered, including
Evidence from a well-conducted multicentre
trial or meta-analysis that incorporated
quality ratings in the analysis
Compelling non-experimental evidence
B Supportive evidence from well-conducted
cohort studies
Supportive evidence from a well-conducted
case-control study
C Supportive evidence from poorly controlled or
uncontrolled studies
Conﬂicting evidence with the weight of
evidence supporting the recommendation
E Expert consensus or clinical experience
Where data are conﬂicting or lacking, advice has been
provided that is based upon expert opinion and experience
in T2DM management
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SGLT2i therapies, in line with the current evi-
dence base and guidelines.
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Risk category Clinical situation Potential implications2-7 Evidence level22
Low risk
Evidence 
supports SGLT2i 
prescribing
First-line (metformin intolerant) A + B + E
Second-line to metformin A + B + E
Third-line (add-on to second-line therapies) A + B + E
Combination with basal insulin or multiple daily injections of insulin¶ A + B + E
Established CVD A + B + E
No history of LLA A
No history of PAD A
Microalbuminuria A
eGFR ≥60 mL/min/1.73m2*‡ A + B + E
Overweight or obese A + B + E
Vulnerable to the effects of hypoglycaemia A
Moderate risk
Prescribe SGLT2i 
with caution
History of PAD LLA risk A + C
Osteoporosis LLA/bone fracture risk A + B + E
Frail/elderly LLA/bone fracture/falls risk A + B
History of foot ulceration LLA risk A
History of fractures Bone fracture risk A + C
GLP-1 receptor agonist combination A + additional evidence required to support decision
Ketogenic diet DKA risk E
High HbA1c levels (86 mmol/mol or 10%)♦ DKA risk A + B + E
Steroid therapy DKA risk/outside of licensed indication E
Cognitive impairment E
BMI <25 DKA risk E
High risk
Do not prescribe 
SGLT2i
Previous LLA LLA risk A + C
Existing diabetic foot ulcers LLA risk A
DKA (or previous episode of DKA) DKA risk E + conflicting evidence
Eating disorders DKA risk E
Rapid progression to insulin (within 1 year) DKA risk E
Latent autoimmune diabetes DKA risk A + E
Excessive alcohol intake DKA risk/outside of licensed indication A + E
Diabetes due to pancreatic disease DKA risk/outside of licensed indication A + E
Stage 3 CKD/eGFR <60 mL/min/1.73m2*‡ Outside of licensed indication
Receiving loop diuretics** Not recommended for use with SGLT2is
Type 1 diabetes (diagnosed or suspected) Outside of licensed indication
Genetic diabetes Outside of licensed indication
Acute illness† Outside of licensed indication
Pregnancy (or suspected pregnancy), planning pregnancy or breastfeeding Outside of licensed indication
Recent major surgery Outside of licensed indication
Fig. 3 Beneﬁt/risk tool. (Abbreviations: T2DM type 2
diabetes mellitus, SGLT2i sodium-glucose cotransporter-2
inhibitor, ADA American Diabetes Association, RCT
randomised controlled trial, BMI body mass index, LLAs
lower leg amputations, PAD peripheral arterial disease, CV
cardiovascular, CVD cardiovascular disease, eGFR estimated
glomerular ﬁltration rate, UTIs urinary tract infections, DKA
diabetic ketoacidosis, CKD chronic kidney disease). }
SGLT2i therapies should be prescribed with caution in
people requiring a rapid reduction in insulin dose, due to
insulinopenia, which may increase DKA risk [2–4]. *Deci-
sions should be based upon recent eGFR measurement, rather
than historical tests. SGLT2i therapies may be initiated in
people with eGFR [3] 60 mL/min/1.73m2. Individuals
already treated with canagliﬂozin or empagliﬂozin who
demonstrate renal decline may continue treatment until
eGFR reaches \45 mL/min/1.73m2. Dapagliﬂozin should
be discontinued for those who demonstrate eGFR\60 mL/
min/1.73m2 [2–4]. Urinary symptoms, due to glucosuria, can
be an issue for people prescribed SGLT2i medicines [2–4].
However, UTIs are relatively rare and these medicines may be
prescribed for people with a history of UTIs. uMonitor
HbA1c levels regularly and cease SGLT2is if elevated levels
continue, following treatment initiation. **SGLT2i treat-
ments are not currently recommended for use alongside loop
diuretics. However, this may be subject to change as the
evidence-base evolves. EMPA-REG and CANVAS CV
outcome trials included subgroups of people with T2DM
who were receiving loop diuretics and ongoing trials aim to
evaluate co-prescribing of these agents [12, 16, 27]. SGLT2i
treatment should be suspended in individuals with acute
illness until fully recovered [2–4, 41, 42]
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